ALISO VIEJO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Clarient, Inc. , a technology and services resource for pathologists, oncologists and the pharmaceutical industry, will report its third quarter ending September 30, 2006 results after the stock market closes on Wednesday, October 25, 2006. That same day management will host a conference call at 5:00 p.m. (EDT) to discuss results of operations.
Listeners may access the call by dialing 877-356-3962 or 706-634-5888 for international callers. A webcast will also be available through the Clarient company website at www.clarientinc.com/investor. Webcast listeners will be able to submit questions by emailing nathan@allencaron.com or clicking on the email address provided on the webcast page. For those unable to participate during the live broadcast, the webcast will be archived shortly after the call and will be available for one year.
About Clarient Inc.
Clarient (www.clarientinc.com) combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The company was formed in 1996 to develop and market the ACIS(R) Automated Cellular Imaging System(TM), an important advance in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide the full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing the most advanced oncology testing and drug development services available. For more information, visit www.clarientinc.com.
About Safeguard
Safeguard Scientifics, Inc. builds value in high-growth, revenue-stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit www.safeguard.com.
Matt Clawson Charlene Lu Allen & Caron, Inc. Clarient, Inc. (949) 474-4300 (949) 362-7345
Clarient, Inc.CONTACT: Charlene Lu of Clarient, Inc., +1-949-362-7345; or Matt Clawsonof Allen & Caron, Inc., +1-949-474-4300, for Clarient, Inc.
